Acute toxicity and effects on hepatic oxidative drug metabolism of mopyridone.
Mopyridone (CAS 82822-14-8) is a new chemotherapeutic with a strong antiviral effect (vs. influenza- and toga viruses) and certain advantages over the chemotherapeutics known so far. Toxicological studies reveal its low oral and intraperitoneal toxicity in mice and rats. The 5- and 14-day administration of mopyridone (37.5 mg/kg b.w., orally) to male rats established a growing tendency to the shortening of hexobarbital sleeping time, associated with moderate changes in the hepatic oxidase activity on the 15th day, most pronounced for amidopyrine N-demethylase (by 37%) and less for benzphetamine N-demethylase (by 17%). Aniline hydroxylase activity was slightly diminished (by 18% and 16%, resp.). No significant changes in the components of the electron-transport chain of cytochrome P-450 were established--the content of cytochrome P-450, cytochrome b-5 and cytochrome C reductase, both after 5- and 14-day mopyridone administration.
Tantcheva
L
L
Institute of Physiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
Galabov
A S
AS
Behar
M
M
Sidzhakova
D
D
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000633:toxicity*; D005260:Female; D006591:Hexobarbital / Q000494:pharmacology; D007928:Lethal Dose 50; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D051379:Mice; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D006899:Mixed Function Oxygenases / Q000378:metabolism; D010084:Oxidation-Reduction; D004364:Pharmaceutical Preparations / Q000378:metabolism; D011744:Pyrimidinones / Q000494:pharmacology / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D012890:Sleep / Q000187:drug effects
D000998:Antiviral Agents; D004364:Pharmaceutical Preparations; D011744:Pyrimidinones; D006591:Hexobarbital; C047314:1-morpholinomethyl-tetrahydro-1(1H)-pyrimidinone; D006899:Mixed Function Oxygenases